Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$135.6KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hing C. Wong
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Beta
- 2.38
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -6.88
Financials
Revenue
$135.6K-96.7%Net Income
$-5.22MEBITDA
$-4.97MFree Cash Flow
$-3.97MEPS (diluted)
$-43.97Shares Outstanding (diluted)
349.6K-92.7%Operating Expenses
$3.06MCash & Debt
$741.3KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.2K | $-7.96M | $-63.78 |
| 2024 | $2.57M | $-30.02M | $-4.62 |
| 2023 | $2.84M | $-24.99M | $-4.20 |
| 2022 | $6.72M | $-14.90M | $-2.52 |
| 2021 | $0.00 | $-12.86M | $-2.16 |
| 2020 | $4.10M | $-5.78M | $-0.96 |
| 2019 | $0.00 | $-7.29M | $-1.26 |
Valuation
HCWBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·12d ago·Neutral
…Announces Pricing of $1.5 Million Private Placement MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”).
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
…constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and IL-15 fusion as a novel moiety with potential app…
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
…Clinical Development Highlights and Financial Results MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-1.08 per share
Typical surprise -220.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-11.58 vs $-1.98miss
- Thu, May 14$2.22 vs $-2.64beat
- Tue, Mar 31$-15.78 vs $-5.04miss
- Fri, Nov 14$-12.12 vs $9.48miss
- Mon, Aug 18$-40.73 vs $10.80miss
- Fri, Mar 28$-19.20 vs $21.60miss
Estimates and results for HCWB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HCWB officers and directors.
- Bought
- $6.3m
- Sold
- —
68 trades
0 trades
- Wong Hing Cboughtdirector, 10 percent owner, officer: Chief Executive Officer·23,210 @ $2.58·$60k·Jul 29, 2026·filing
- Flowers Leebought
- Garrett Scott Tbought
- Wong Hing Cboughtdirector, 10 percent owner, officer: Chief Executive Officer·113,879 @ $1.41·$160k·May 22, 2026·filing
- Wong Hing Cboughtdirector, 10 percent owner, officer: Chief Executive Officer·113,879 @ $1.28·$146k·May 22, 2026·filing
- Garrett Scott Tbought
- Garrett Scott Tbought
- Byam Rebeccabought
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HCWB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.